Back to trial

NCT04224272

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Version 17 to 18 · Jazz Pharmaceuticals

Patch inspector

Version 17 to 18

12 operations 3 path groups ctgov_internal_history
ClinicalTrials.gov
Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.
Plain-language summary

Manual review pending.

Rules fired

None recorded.

Value signals
[
  {
    "paths": [
      "/protocolSection/outcomesModule/primaryOutcomes/2/description",
      "/protocolSection/outcomesModule/primaryOutcomes/2/reviewUnit",
      "/protocolSection/outcomesModule/primaryOutcomes/2/timeFrame"
    ],
    "signal": "results_reconciliation_outcome_suppression",
    "category": "results_reconciliation",
    "severity": "low"
  }
]
Provenance
Source
ctgov_internal_history
Fetched
2026-06-18 18:58:09+00
Raw hash
3e5b164f2bbe030a40523ea7f9e60d0f38fb18c627fae6b754d9390c497ad356
Payload
Source URL
Primary outcomes Outcome measures that define the trial's primary evidence target. Triage: Critical 3 ops
replace /protocolSection/outcomesModule/primaryOutcomes/2/description
Triage: Critical
Primary Outcome Change Operation 6
Matched rules
  • primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.
Before
Progression-free survival at 6 months (PFS6) is defined as having a progression-free survival time greater than or equal to 24 weeks at the time of analysis where PFS time is defined as the time from the first dose of ZW25, palbociclib, and/or fulvestrant to the date of documented disease progression (per RECIST 1.1) or death from any cause.
After
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).
replace /protocolSection/outcomesModule/primaryOutcomes/2/timeFrame
Triage: Critical
Primary Outcome Change Operation 7
Matched rules
  • primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.
Before
6 months from first dose of any study drug to the date of documented disease progression or death, up to approximately 2 years 10 months
After
6 months from first dose of any study drug to the date of documented disease progression or death
remove /protocolSection/outcomesModule/primaryOutcomes/2/reviewUnit
Triage: Critical
Primary Outcome Change Operation 8
Matched rules
  • primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.
Before
{
  "resetReasons": [
    "There does not appear to be sufficient information to understand the Time Frame."
  ]
}
Other registry fields Changes outside the current high-signal rule families. Triage: Uncategorized 6 ops
replace /protocolSection/statusModule/statusVerifiedDate
Triage: Uncategorized
Uncategorized Operation 1
Before
2024-04
After
2024-08
replace /protocolSection/statusModule/lastUpdateSubmitDate
Triage: Uncategorized
Uncategorized Operation 2
Before
2024-04-26
After
2024-08-13
replace /protocolSection/statusModule/lastUpdatePostDateStruct/date
Triage: Uncategorized
Uncategorized Operation 3
Before
2024-05-24
After
2024-08-14
add /protocolSection/statusModule/resultsFirstSubmitQcDate
Triage: Uncategorized
Uncategorized Operation 4
After
2024-08-13
add /protocolSection/statusModule/resultsFirstPostDateStruct
Triage: Uncategorized
Uncategorized Operation 5
After
{
  "date": "2024-08-14",
  "type": "ACTUAL"
}
remove /annotationSection
Triage: Uncategorized
Uncategorized Operation 12
Before
{
  "annotationModule": {
    "unpostedAnnotation": {
      "unpostedEvents": [
        {
          "date": "2024-05-23",
          "type": "RESET"
        }
      ],
      "unpostedResponsibleParty": "Jazz Pharmaceuticals"
    }
  }
}
Results outcome measures Posted result outcome measures and result-level endpoint data. Triage: Uncategorized 3 ops
replace /resultsSection/outcomeMeasuresModule/outcomeMeasures/3/description
Triage: Uncategorized
Uncategorized Operation 9
Before
Progression-free survival at 6 months (PFS6) is defined as having a progression-free survival time greater than or equal to 24 weeks at the time of analysis where PFS time is defined as the time from the first dose of ZW25, palbociclib, and/or fulvestrant to the date of documented disease progression (per RECIST 1.1) or death from any cause.
After
The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days).
replace /resultsSection/outcomeMeasuresModule/outcomeMeasures/3/timeFrame
Triage: Uncategorized
Uncategorized Operation 10
Before
6 months from first dose of any study drug to the date of documented disease progression or death, up to approximately 2 years 10 months
After
6 months from first dose of any study drug to the date of documented disease progression or death
remove /resultsSection/outcomeMeasuresModule/outcomeMeasures/3/reviewUnit
Triage: Uncategorized
Uncategorized Operation 11
Before
{
  "resetReasons": [
    "There does not appear to be sufficient information to understand the Time Frame."
  ]
}
Raw JSON Patch
[
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/statusVerifiedDate",
    "value": "2024-08"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdateSubmitDate",
    "value": "2024-08-13"
  },
  {
    "op": "replace",
    "path": "/protocolSection/statusModule/lastUpdatePostDateStruct/date",
    "value": "2024-08-14"
  },
  {
    "op": "add",
    "path": "/protocolSection/statusModule/resultsFirstSubmitQcDate",
    "value": "2024-08-13"
  },
  {
    "op": "add",
    "path": "/protocolSection/statusModule/resultsFirstPostDateStruct",
    "value": {
      "date": "2024-08-14",
      "type": "ACTUAL"
    }
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/primaryOutcomes/2/description",
    "value": "The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days)."
  },
  {
    "op": "replace",
    "path": "/protocolSection/outcomesModule/primaryOutcomes/2/timeFrame",
    "value": "6 months from first dose of any study drug to the date of documented disease progression or death"
  },
  {
    "op": "remove",
    "path": "/protocolSection/outcomesModule/primaryOutcomes/2/reviewUnit"
  },
  {
    "op": "replace",
    "path": "/resultsSection/outcomeMeasuresModule/outcomeMeasures/3/description",
    "value": "The progression-free survival at 6 months (PFS6) is a binary endpoint variable based on the progression-free survival (PFS) time, defined as the proportion of participants having PFS time greater than or equal to 24 weeks (168 days)."
  },
  {
    "op": "replace",
    "path": "/resultsSection/outcomeMeasuresModule/outcomeMeasures/3/timeFrame",
    "value": "6 months from first dose of any study drug to the date of documented disease progression or death"
  },
  {
    "op": "remove",
    "path": "/resultsSection/outcomeMeasuresModule/outcomeMeasures/3/reviewUnit"
  },
  {
    "op": "remove",
    "path": "/annotationSection"
  }
]